US FDA reverses course on Regenxbio’s rare-disease gene therapy, backs accelerated approval bid

Investing.com Gold reports: US FDA reverses course on Regenxbio’s rare-disease gene therapy, backs accelerated approval bid. Full body text was unavailable at ingest time, so this brief is based on headline context.